bacterial diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages six weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitides serogroups C and Y and Haemophilus influenza type b. […]